Zydus gets DCGI approval for emergency use of Virafin in treating moderate COVID-19 cases
Coronavirus India: The Drugs Controller General of India (DGCI) on Friday approved the emergency use for Zydus Cadila's Pegylated Interferon alpha-2b ‘Virafin’ for treating moderate COVID-19 infection for adults.
Zydus Cadila announced that it has received emergency use approval from DCGI to use Virafin for the treatment of moderate COVID-19 infections.
Also Read | Triple mutation variant in India emerges as fresh worry amid battle against coronavirus
As per the report, a single-dose subcutaneous regimen of the drug will make the treatment of COVID-19 more convenient.
The company had said that if administered early on during COVID-19, Virafin may help patients recover faster and avoid much of the complications. It will be available on the prescription of a medical specialist.
Also Read | Coronavirus: Chandigarh says no to week-long or weekend lockdown
It has also stated that in multicentric trials conducted in 20-25 centers across the country, Virgin showed a lesser need for supplemental oxygen.
It indicated that it was able to control respiratory distress and failure which has been one of the major challenges while treating COVID-19. The drug has shown efficacy against other viral infections as well, the company added.
India on Friday added a record over 3.32 lakh new coronavirus cases taking the country's tally to 1,62,63,695. The active cases have crossed the 24-lakh mark, according to the Union Health Ministry data updated on Friday.
Click here to follow PTC News on Twitter
-PTC News
